IL147150A0 - Method for treating chronic pain using mek inhibitors - Google Patents
Method for treating chronic pain using mek inhibitorsInfo
- Publication number
- IL147150A0 IL147150A0 IL14715000A IL14715000A IL147150A0 IL 147150 A0 IL147150 A0 IL 147150A0 IL 14715000 A IL14715000 A IL 14715000A IL 14715000 A IL14715000 A IL 14715000A IL 147150 A0 IL147150 A0 IL 147150A0
- Authority
- IL
- Israel
- Prior art keywords
- chronic pain
- treating chronic
- mek inhibitors
- mek
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14441899P | 1999-07-16 | 1999-07-16 | |
PCT/US2000/018345 WO2001005390A2 (en) | 1999-07-16 | 2000-07-05 | Method for treating chronic pain using mek inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IL147150A0 true IL147150A0 (en) | 2002-08-14 |
Family
ID=22508500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14715000A IL147150A0 (en) | 1999-07-16 | 2000-07-05 | Method for treating chronic pain using mek inhibitors |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1202731A2 (en) |
JP (1) | JP2003504398A (en) |
KR (1) | KR20020015376A (en) |
CN (1) | CN1358094A (en) |
AU (1) | AU6068600A (en) |
CA (1) | CA2377092A1 (en) |
CO (1) | CO5190704A1 (en) |
HU (1) | HUP0202319A3 (en) |
IL (1) | IL147150A0 (en) |
PE (1) | PE20010546A1 (en) |
PL (1) | PL352835A1 (en) |
WO (1) | WO2001005390A2 (en) |
ZA (1) | ZA200109906B (en) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR035971A1 (en) | 2001-05-16 | 2004-07-28 | Cephalon Inc | METHODS FOR THE TREATMENT AND PREVENTION OF PAIN |
US20030008807A1 (en) * | 2001-06-14 | 2003-01-09 | The Regents Of The University Of California | Novel signaling pathway for the production of inflammatory pain and neuropathy |
DE60330227D1 (en) * | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
TW200406203A (en) * | 2002-03-13 | 2004-05-01 | Array Biopharma Inc | N3 alkylated banzimidazole derivatives as MEK inhibitors |
GB0213383D0 (en) * | 2002-06-11 | 2002-07-24 | Cambridge Biotechnology Ltd | Therapeutic conditions |
US20050004186A1 (en) * | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
EP1651214B1 (en) * | 2003-07-24 | 2009-09-16 | Warner-Lambert Company LLC | Benzimidazole derivatives as mek inhibitors |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
KR101127201B1 (en) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | Benzimidazole derivatives: preparation and pharmaceutical applications |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
CN1905873A (en) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Bicyclic inhibitors of MEK and methods of use thereof |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
BRPI0416852A (en) | 2003-11-21 | 2007-02-27 | Array Biopharma Inc | akt kinase inhibitors |
MY149960A (en) | 2005-05-18 | 2013-11-15 | Array Biopharma Inc | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases |
MY177122A (en) | 2005-06-23 | 2020-09-07 | Array Biopharma Inc | Process for preparing benzimidazole compounds |
ATE504565T1 (en) | 2005-10-07 | 2011-04-15 | Exelixis Inc | AZETIDINES AS MEK INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISEASES |
ATE493418T1 (en) | 2006-07-06 | 2011-01-15 | Array Biopharma Inc | DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS |
SI2054418T1 (en) | 2006-07-06 | 2012-02-29 | Array Biopharma Inc | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
AU2007269052B2 (en) | 2006-07-06 | 2014-10-23 | Array Biopharma Inc. | Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors |
CN101605540A (en) | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | Use the method for mek inhibitor |
RU2486181C2 (en) | 2007-07-05 | 2013-06-27 | Эррэй Биофарма Инк. | Pyrimidyl cyclopentanes as akt/protein kinase inhibitors |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
ES2533557T3 (en) | 2007-07-05 | 2015-04-13 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
SI2690101T1 (en) | 2007-12-19 | 2015-10-30 | Genentech, Inc. | 5-Anilinoimidazopyridines and Methods of Use |
AU2008343062B2 (en) | 2007-12-19 | 2013-03-07 | Genentech, Inc. | 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
KR20100099185A (en) | 2007-12-21 | 2010-09-10 | 제넨테크, 인크. | Azaindolizines and methods of use |
WO2009089459A1 (en) | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
MX2010007546A (en) | 2008-01-09 | 2010-09-30 | Array Biopharma Inc | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor. |
WO2010003022A1 (en) | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Isoindolone derivatives as mek kinase inhibitors and methods of use |
ES2399384T3 (en) | 2008-11-10 | 2013-04-01 | Bayer Schering Pharma Ag | Sulfonamido substituted phenoxybenzamides |
CA2777071A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
EP2491016A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
EP2632899A1 (en) | 2010-10-29 | 2013-09-04 | Bayer Intellectual Property GmbH | Substituted phenoxypyridines |
TR201815685T4 (en) | 2011-04-01 | 2018-11-21 | Genentech Inc | Combinations of act and mec inhibitory compounds for the treatment of cancer. |
US9150549B2 (en) | 2011-04-01 | 2015-10-06 | Genentech, Inc. | Combinations of AKT inhibitor compounds and erlotinib, and methods of use |
ES2396764B1 (en) | 2011-11-02 | 2013-12-19 | Universidad Autónoma de Madrid | P38 INHIBITING DRUGS AND APPLICATIONS. |
JP5977837B2 (en) | 2011-12-21 | 2016-08-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | Hepatitis B antiviral agent |
CN103204827B (en) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | Benzothiadiazole compounds as protein kinase inhibitors, and preparation method and application thereof |
NZ743499A (en) | 2012-08-28 | 2019-09-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
IN2015DN03928A (en) | 2012-10-12 | 2015-10-02 | Exelixis Inc | |
HUE065433T2 (en) * | 2012-10-19 | 2024-05-28 | Array Biopharma Inc | Formulation comprising a mek inhibitor |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
MX353412B (en) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b. |
JO3603B1 (en) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
HUE039152T2 (en) | 2013-07-25 | 2018-12-28 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
ES2655518T3 (en) | 2013-10-23 | 2018-02-20 | Janssen Sciences Ireland Uc | Carboxamide derivatives and their use as medicines for the treatment of hepatitis B |
CN104774188B (en) * | 2014-01-15 | 2019-10-11 | 江苏恒瑞医药股份有限公司 | Benzo-heterocycle or benzo hetero-aromatic ring analog derivative, preparation method and its application in medicine |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
WO2015120178A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
AP2016009257A0 (en) | 2014-02-06 | 2016-06-30 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
CN107847762A (en) | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | Azacyclooctane and azacyclo- nonane derivatives and the method for treating hepatitis B infection |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
AR106192A1 (en) | 2015-09-29 | 2017-12-20 | Novira Therapeutics Inc | CRYSTAL FORMS OF AN ANTIVIRAL AGENT AGAINST HEPATITIS B |
AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
AR108257A1 (en) | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | POLYMORPHIC FORMS OF 3- [2-BUTIL-1- (2-DIETILAMINO-ETIL) -1H-BENCIMIDAZOL-5-IL] -N-HYDROXY-ACRYLAMIDE AND USES OF THE SAME |
EA202092171A1 (en) | 2018-03-14 | 2020-12-01 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | DOSING SCHEME OF THE MODULATOR ASSEMBLY OF CAPSIDE |
CA3127152A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
MA55879A (en) | 2019-05-06 | 2022-03-16 | Janssen Sciences Ireland Unlimited Co | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR DISEASES INDUCED BY HEPATITIS B VIRUS |
CN110981819B (en) * | 2019-12-24 | 2022-07-01 | 广西师范大学 | Quinoxaline signal channel inhibitor and preparation method and application thereof |
CN114788867A (en) * | 2022-04-24 | 2022-07-26 | 天津医科大学总医院 | Application of Map2k1 as therapeutic target of postchemotherapy neuralgia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6251943B1 (en) * | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
SK9832001A3 (en) * | 1999-01-13 | 2003-02-04 | Warner Lambert Co | Benzoheterocycles and their use as MEK inhibitors |
-
2000
- 2000-07-05 EP EP00947013A patent/EP1202731A2/en not_active Withdrawn
- 2000-07-05 IL IL14715000A patent/IL147150A0/en unknown
- 2000-07-05 CA CA002377092A patent/CA2377092A1/en not_active Abandoned
- 2000-07-05 KR KR1020027000589A patent/KR20020015376A/en not_active Application Discontinuation
- 2000-07-05 JP JP2001510447A patent/JP2003504398A/en active Pending
- 2000-07-05 WO PCT/US2000/018345 patent/WO2001005390A2/en not_active Application Discontinuation
- 2000-07-05 HU HU0202319A patent/HUP0202319A3/en unknown
- 2000-07-05 PL PL00352835A patent/PL352835A1/en unknown
- 2000-07-05 AU AU60686/00A patent/AU6068600A/en not_active Abandoned
- 2000-07-05 CN CN00809478A patent/CN1358094A/en active Pending
- 2000-07-14 PE PE2000000704A patent/PE20010546A1/en not_active Application Discontinuation
- 2000-07-14 CO CO00053306A patent/CO5190704A1/en not_active Application Discontinuation
-
2001
- 2001-11-30 ZA ZA200109906A patent/ZA200109906B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU6068600A (en) | 2001-02-05 |
PL352835A1 (en) | 2003-09-08 |
EP1202731A2 (en) | 2002-05-08 |
WO2001005390A3 (en) | 2001-05-17 |
CO5190704A1 (en) | 2002-08-29 |
PE20010546A1 (en) | 2001-06-04 |
ZA200109906B (en) | 2003-05-28 |
WO2001005390A2 (en) | 2001-01-25 |
KR20020015376A (en) | 2002-02-27 |
HUP0202319A3 (en) | 2004-12-28 |
HUP0202319A2 (en) | 2002-10-28 |
JP2003504398A (en) | 2003-02-04 |
CN1358094A (en) | 2002-07-10 |
CA2377092A1 (en) | 2001-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL147150A0 (en) | Method for treating chronic pain using mek inhibitors | |
HUP0202180A2 (en) | Method for treating chronic pain using mek inhibitors | |
IL147619A0 (en) | Method for treating chronic pain using mek inhibitors | |
HUP0202381A3 (en) | Method for treating chronic pain using mek inhibitors | |
EP1215963A4 (en) | Methods for treating neuropathic pain using hetreoarylmethanesulfonamides | |
IL126203A0 (en) | Method for treating pain | |
EP0906104A4 (en) | Method for treating pain | |
AU7963200A (en) | Improved method and apparatus for water treatment | |
AU2003218352A8 (en) | Method and system for treating tissue swelling | |
IL209352A0 (en) | 4-tetrazolyl-4phenylpiperidine derivatives for treating pain | |
AU9035498A (en) | Method for treating pain | |
AU1484202A (en) | Method for treating films | |
EP1139398A4 (en) | Method and apparatus for surface treatment | |
EP1446087A4 (en) | Method for treating non-neuropathic pain | |
IL164219A0 (en) | Method for treating and preventing hyparathyroidism | |
PL342076A1 (en) | Method of treating surfaces | |
AU7331300A (en) | Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome | |
EP1007046A4 (en) | Method for treatment of chronic bronchitis | |
IL126064A0 (en) | Method for treating pain | |
IL126063A0 (en) | Method for treating migraine pain | |
AU2002232606A1 (en) | Method and apparatus for treating breakthrough pain | |
EP1165852A4 (en) | Surface treatment method and treatment apparatus | |
AU9034798A (en) | Method for treating pain | |
GB0118883D0 (en) | Method for treating objects | |
GB0123898D0 (en) | Method for treating objects |